RiverVest Venture Partners Co-leads $86 million Series A Financing for St. Louis-founded Startup Tioma
"This is a fantastic example of what St. Louis-based innovation, talent and resources can do to build biopharma companies that will make a difference," said John McKearn, RiverVest managing director and Tioma board chairman.
RiverVest's Fund II Continues to Perform in Top 5% of VC funds
RiverVest Fund II continues to be among the top performers among all US VC funds, according to Cambridge Associates’ Venture Capital Index and Benchmark Statistics most recent quarterly report. When compared with other 2006 vintage year funds across all industry sectors, RiverVest Fund II ranks in the top five percent.
RiverVest adds Analyst in St. Louis Office
Nakul Tandon, who recently received a Masters of Finance degree from Washington University in St. Louis, has joined RiverVest as an analyst, performing financial analysis in connection with portfolio company financings and M&A transactions.
RiverVest sponsored the Emerging Venture Leaders Summit in St. Louis this summer, where Managing Director Niall O'Donnell reflected on his career journey, what has worked, what hasn't and where he sees venture investing going.
Allakos, Inc., San Carlos, CA is a clinical stage company developing antiobodies intended to treat severe allergic diseases and other diseases characterized by excess activity of mast cells and eosinophils.
Securus Medical Group, Inc., Cleveland, OH is a later-stage medical device company developing a 510(k)-approved clincal tool to monitor temperature within body cavities in order to avoid thermal injury to tissue due to energy from various sources.
RiverVest Venture Partners® is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. Because of its extensive operating expertise, RiverVest is able to help entrepreneurs achieve near-term objectives that position their companies for exit.